Inflammation in end-stage renal disease: sources, consequences, and therapy.
about
Diagnosis and Management of Cardiovascular Disease in Advanced and End-Stage Renal DiseaseOptimizing haemodialysate compositionRepositioning Clofazimine as a Macrophage-Targeting Photoacoustic Contrast Agent.Vascular calcification: When should we interfere in chronic kidney disease patients and how?Stop chronic kidney disease progression: Time is approachingHDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approachEffect of exercise on cardiac tissue oxidative and inflammatory mediators in chronic kidney diseaseThe systemic nature of CKD.Glucose in the dialysate: historical perspective and possible implications?N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure researchFactors Associated with Decreased Lean Tissue Index in Patients with Chronic Kidney Disease.Low levels of vitamin C in dialysis patients is associated with decreased prealbumin and increased C-reactive proteinAdiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease.IL-1β receptor antagonist reduces inflammation in hemodialysis patientsPlasma S100A12 level is associated with cardiovascular disease in hemodialysis patients.Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney diseaseCross-over study of influence of oral vitamin C supplementation on inflammatory status in maintenance hemodialysis patients.Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filtersTranscriptome analysis in patients with chronic kidney disease on hemodialysis disclosing a key role for CD16+CX3CR1+ monocytes.Emerging drugs for renal failure.Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients.Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease.In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide.The pattern of inflammation and a potential new clinical meaning and usefulness of C-reactive protein in end-stage renal failure patients.Symmetric dimethylarginine as a proinflammatory agent in chronic kidney diseaseAssociations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patientsChronic Inflammation and Coronary Atherosclerosis in Patients with End-Stage Renal DiseaseHemodialysis and water quality.Immunomodulating effects of vitamin D analogs in hemodialysis patients.Statins for renal patients: a fiddler on the roof?Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences.Mechanisms of dyslipidemia of chronic renal failure.Protecting the endothelium: a new focus for management of chronic kidney disease.Inflammatory marker but not adipokine predicts mortality among long-term hemodialysis patients.Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production.Hypoalbuminaemia--a marker of cardiovascular disease in patients with chronic kidney disease stages II-IV.Is inflammation a new risk factor of depression in haemodialysis patients?The platelet-to-lymphocyte ratio as an inflammation marker in non-dipper hypertensive patientsSerum Concentrations of F2-Isoprostanes and 4-Hydroxynonenal in Hemodialysis Patients in Relation to Inflammation and Renal AnemiaFactors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study.
P2860
Q26739024-F9846E35-ABF5-457F-9EA1-B144F09B2928Q26785879-63B8BB4C-350C-4B9A-A824-32F0CAD801B1Q27327281-9CCF1069-AAC3-4B05-9AD1-F69C8763C99FQ28071582-783DC69A-2CEF-428F-8559-2217631939A5Q28078020-E4080416-A3AA-4F76-900A-4CB2CE86FA4CQ28481613-82305F78-6F87-40D4-B567-412A516AB28AQ28565167-7C355360-4402-45DC-B666-C2AD763EDB05Q30234695-0696A0B0-39E7-476A-8CB3-29FDAD30CF6CQ30445919-0BBE50A2-47A5-49BA-B9D9-A4DC7D8CCB99Q33604039-4855560F-E7FB-430C-A13C-A9DFD90022DCQ33749191-A75206F4-2C93-4DEB-8983-76276D3F3F99Q33891454-D2E8A44D-1092-4CC4-97C3-3839A22CD8F8Q34555325-D7C044F1-8B0E-41EB-B1CA-B9046843837AQ34695324-C1152800-C956-4264-9F0E-BBEBC138BEB4Q34751797-E0095B90-6BEA-4AE2-BE56-94ACF1629930Q35033613-1E8A0AFC-75C2-400D-9559-8B8E50849B28Q35042578-BBC929D5-9788-4074-9EE0-0541663F16ECQ35164180-52F91DF9-8360-420B-B845-2DCD10D3EDF6Q35241188-1FE7F67A-059D-4B8A-BE49-CC2076EFE9E9Q35602657-5A9B9CF1-20C6-46DC-BF37-451FA0915DF8Q35622521-733499FF-BF4B-45DF-84B3-62D00AFE6DCEQ35747579-F363DBF9-C4AA-4A58-9C8E-437F323A588FQ35760064-33543AE1-9674-477A-9E14-1D76A59DD824Q35954117-0A276A34-CC70-40CF-8DC1-2818A065CD6FQ35985806-70AE6DA7-AAF9-4B06-8D5E-360BC239A270Q36034508-B0724607-2CB7-4D84-A678-AB76179DBF05Q36036008-585E5BFE-FB6C-4F89-85CC-D2E0DFB2FAFAQ36131679-DCCD3F76-7794-47C0-A507-A9E3AC7FE1E9Q36285501-17123A79-482E-428F-B4CD-4C0C2A530F03Q36361057-C4B7353B-FE39-4E99-816E-DBEE7824210EQ36364965-AE952AB5-E515-4EE8-8CE7-CD517059203CQ36379589-83D7D180-7EA7-4C7A-875A-2A6869210EEAQ36379593-43179DB7-A202-4370-A46A-C9F4B156E78BQ36417503-2598E98F-2235-4E57-92CA-55EC81D34358Q36721867-9540F463-1634-4928-BB48-1ED81F85F272Q36973766-DC12FB6C-0294-49DC-9760-CD977C476E9DQ37067983-3B009DE4-415A-4D7B-99EE-6DC49DDAD605Q37078439-8B566CDB-C8F0-4E75-833A-D65EDACA6AD8Q37207365-621E1FA0-A266-43A4-B3FD-9CF4562D71D4Q37257340-F2DECFA6-141A-4D14-9B90-618677B77FDB
P2860
Inflammation in end-stage renal disease: sources, consequences, and therapy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Inflammation in end-stage renal disease: sources, consequences, and therapy.
@ast
Inflammation in end-stage renal disease: sources, consequences, and therapy.
@en
Inflammation in end-stage renal disease: sources, consequences, and therapy.
@nl
type
label
Inflammation in end-stage renal disease: sources, consequences, and therapy.
@ast
Inflammation in end-stage renal disease: sources, consequences, and therapy.
@en
Inflammation in end-stage renal disease: sources, consequences, and therapy.
@nl
prefLabel
Inflammation in end-stage renal disease: sources, consequences, and therapy.
@ast
Inflammation in end-stage renal disease: sources, consequences, and therapy.
@en
Inflammation in end-stage renal disease: sources, consequences, and therapy.
@nl
P2860
P1433
P1476
Inflammation in end-stage renal disease: sources, consequences, and therapy.
@en
P2093
Anders Alvestrand
P2860
P304
P356
10.1046/J.1525-139X.2002.00083.X
P577
2002-09-01T00:00:00Z